We are live on
!
Find out more
BCA
Benchmark Capital Advisors Portfolio holdings
AUM
$101M
1-Year Est. Return
0.8%
This Fund
S&P 500
This Quarter
Est. Return
+9.68%
1 Year Est. Return
-0.8%
3 Year Est. Return
+29.53%
5 Year Est. Return
+43.22%
10 Year Est. Return
–
AUM
$139M
AUM Growth
+$9.62M
(+7.4%)
Cap. Flow
+$2.42M
Cap. Flow
% of AUM
1.74%
Top 10 Holdings %
Top 10 Hldgs %
27.84%
Holding
157
New
14
Increased
39
Reduced
52
Closed
19
Avg Time Held
0.9
quarters
Top 10 Avg Time Held
0.7
quarters
Top 20 Avg Time Held
0.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vodafone
VOD
|
+$2.49M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.34M |
| 3 |
GEN MOTORS CORP
GM
|
+$2.05M |
| 4 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$1.37M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ligand Pharmaceuticals
LGND
|
+$1.98M |
| 2 |
Howard Hughes
HHH
|
+$1.7M |
| 3 |
DNY
DONNELLEY R R & SONS CO
DNY
|
+$1.39M |
| 4 |
Newmont
NEM
|
+$860K |
| 5 |
Corning
GLW
|
+$834K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 20.67% |
| 2 | Energy | 14.21% |
| 3 | Technology | 10.78% |
| 4 | Healthcare | 9.81% |
| 5 | Consumer Discretionary | 9.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
GEN MOTORS CORP
GM
| $5.98M | 4.3% |
166,350
+56,850
| +52% | +$2.05M |
2013 Q2
1 quarter
|
|
|
2
Vodafone
VOD
$35.7B
| $4.08M | 2.93% |
113,747
+78,627
| +224% | +$2.49M |
2013 Q2
1 quarter
|
|
3
GE Aerospace
GE
$320B
| $3.97M | 2.85% |
34,648
-668
| -2% | -$76.6K |
2013 Q2
1 quarter
|
|
4
Hercules Capital
HTGC
$3.1B
| $3.83M | 2.75% |
251,296
-300
| -0.1% | -$4.35K |
2013 Q2
1 quarter
|
|
5
BK Technologies
BKTI
$272M
| $3.79M | 2.72% |
287,511
+10,900
| +4% | +$163K |
2013 Q2
1 quarter
|
|
|
CORE
6
DELISTED
Core Mark Holding Co., Inc.
CORE
| $3.77M | 2.71% |
227,200
| – | – |
2013 Q2
1 quarter
|
|
7
Pfizer
PFE
$162B
| $3.46M | 2.48% |
126,849
-14,703
| -10% | -$400K |
2013 Q2
1 quarter
|
|
8
Devon Energy
DVN
$53.9B
| $3.38M | 2.42% |
58,470
-1,225
| -2% | -$70K |
2013 Q2
1 quarter
|
|
|
YHOO
9
DELISTED
Yahoo Inc
YHOO
| $3.35M | 2.41% |
101,000
+11,000
| +12% | +$311K |
2013 Q2
1 quarter
|
|
10
Johnson & Johnson
JNJ
$636B
| $3.16M | 2.27% |
36,485
+5,400
| +17% | +$484K |
2013 Q2
1 quarter
|
|
11
Clean Energy Fuels
CLNE
$311M
| $2.77M | 1.99% |
216,700
+8,000
| +4% | +$103K |
2013 Q2
1 quarter
|
|
|
SPA
12
DELISTED
Sparton
SPA
| $2.64M | 1.9% |
103,702
-9,900
| -9% | -$196K |
2013 Q2
1 quarter
|
|
13
DELISTED
Hess
HES
| $2.55M | 1.83% |
33,000
+10,000
| +43% | +$745K |
2013 Q2
1 quarter
|
|
|
14
Bristol-Myers Squibb
BMY
$118B
| $2.47M | 1.77% |
+53,400
| New | +$2.34M |
2013 Q3
0 quarters
|
|
15
Cisco
CSCO
$455B
| $2.42M | 1.74% |
103,424
-12,450
| -11% | -$309K |
2013 Q2
1 quarter
|
|
16
Mondelez International
MDLZ
$78.9B
| $2.41M | 1.73% |
76,650
-200
| -0.3% | -$6.2K |
2013 Q2
1 quarter
|
|
17
Microsoft
MSFT
$4.02T
| $2.4M | 1.72% |
72,000
-25,077
| -26% | -$825K |
2013 Q2
1 quarter
|
|
|
PCYC
18
DELISTED
PHARMACYCLICS INC
PCYC
| $2.38M | 1.71% |
17,250
+12,350
| +252% | +$1.37M |
2013 Q2
1 quarter
|
|
19
Wells Fargo
WFC
$252B
| $2.37M | 1.7% |
57,275
-750
| -1% | -$32K |
2013 Q2
1 quarter
|
|
20
Apple
AAPL
$4.98T
| $2.35M | 1.69% |
138,320
+27,160
| +24% | +$450K |
2013 Q2
1 quarter
|
|
|
CVA
21
DELISTED
Covanta Holding Corporation
CVA
| $2.07M | 1.49% |
96,900
-25,200
| -21% | -$529K |
2013 Q2
1 quarter
|
|
22
DELISTED
Seadrill Limited Common Stock
SDRL
| $2M | 1.44% |
166
+16
| +11% | +$189K |
2013 Q2
1 quarter
|
|
|
KRFT
23
DELISTED
KRAFT FOODS GROUP INC COM STK (VA)
KRFT
| $1.99M | 1.43% |
37,937
-1,616
| -4% | -$88.5K |
2013 Q2
1 quarter
|
|
|
CLNY
24
DELISTED
Colony Capital, Inc.
CLNY
| $1.88M | 1.35% |
93,900
+3,500
| +4% | +$70.7K |
2013 Q2
1 quarter
|
|
25
Redwood Trust
RWT
$384M
| $1.74M | 1.25% |
88,400
-200
| -0.2% | -$3.56K |
2013 Q2
1 quarter
|
|
Similar funds
OIMU
7A
JCP
DCM
BCEM
QAM
CFA
BPV
Benchmark Capital Advisors's Q3 2013 Portfolio in Review
As of Q3 2013, Benchmark Capital Advisors held 157 positions worth $139M, up 7.4% from $130M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Benchmark Capital Advisors's Q3 2013 filing shows 14 new, 39 increased, 52 reduced and 19 closed positions. Its largest new stake was Bristol-Myers Squibb: 53,400 shares worth $2.47M. The largest sale was Ligand Pharmaceuticals, an estimated $1.98M.
By sector, the portfolio is most concentrated in Miscellaneous at 21% of assets, down from 24% a quarter earlier, followed by Energy and Technology.
- Benchmark Capital Advisors's largest Q3 2013 buy was Bristol-Myers Squibb: 53,400 shares worth $2.47M.
- Benchmark Capital Advisors added most to Vodafone in Q3 2013, an estimated $2.49M increase.
- Benchmark Capital Advisors's biggest Q3 2013 reduction was Howard Hughes, cutting an estimated $1.7M.
- Benchmark Capital Advisors fully exited Ligand Pharmaceuticals in Q3 2013, selling an estimated $1.98M.
- Benchmark Capital Advisors's ten largest holdings make up 28% of its $139M portfolio in Q3 2013.
- Benchmark Capital Advisors opened 14 new positions and closed 19 in Q3 2013.
- Benchmark Capital Advisors's portfolio value rose 7.4% quarter-over-quarter to $139M.
Based on Benchmark Capital Advisors's 13F filing for Q3 2013, filed 23 Oct 2013.